MediciNova Inc MNOV
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2006-12-01 |
| Shares Out. | 49,220,000 |
| Website | medicinova.com/ ↗ |
| Phone | 18583731500 |
| Employees | 6 |
| Revenue | $186,984 |
| Gross Profit | $186,984 |
| Net Income | -$2.6M |
| Free Cash Flow | -$9.5M |
| Total Assets | $42.7M |
| Total Liabilities | $3.3M |
| Equity | $39.4M |
About MediciNova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
MediciNova Inc is a publicly traded company under the ticker symbol MNOV on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)